Literature DB >> 1878756

Short-term effects of administration of anticonvulsant drugs on free carnitine and acylcarnitine in mouse serum and tissues.

M F Camiña1, I Rozas, M Gómez, J M Paz, C Alonso, S Rodriguez-Segade.   

Abstract

1. The short-term evolution of concentrations of free carnitine and acylcarnitine was studied in the serum, liver, kidney, heart and skeletal muscle of mice after administration of single therapeutic doses of the anticonvulsant drugs, valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHT) and phenobarbitone (PHB). 2. The effects of the drugs were immediate but transitory, control levels of free carnitine and acylcarnitine having been recovered or almost recovered in serum and in all tissues 8 h post administration (p.a.). 3. VPA was the only drug that significantly reduced free carnitine concentration in serum, which recovered control levels by 4 h p.a. 4. All the drugs studied brought about marked deficits of serum acylcarnitine, which had disappeared 2 h p.a. in the case of VPA and not until 8 h p.a. for CBZ, PHT or PHB. 5. The minimum concentrations of free carnitine and acylcarnitine in serum were invariably associated with the maximum concentration of drug in serum. 6. Free carnitine concentration was not affected by VPA in any tissue, PHT and PHB brought about significant deficits in heart and kidney, and CBZ a significant deficit in muscle. 7. Acylcarnitine concentration was significantly reduced in heart, kidney and muscle by CBZ, PHT and PHB, but in liver the effects of all drugs were very small. 8. These results are compatible with the hypothesis that the primary cause of anticonvulsant-induced alteration of carnitine metabolism is interference with renal reabsorption of carnitine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1878756      PMCID: PMC1908100          DOI: 10.1111/j.1476-5381.1991.tb12320.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Effects of acute valproate administration on carnitine metabolism in mouse serum and tissues.

Authors:  I Rozas; M F Camiña; J M Paz; C Alonso; M Castro-Gago; S Rodriguez-Segade
Journal:  Biochem Pharmacol       Date:  1990-01-01       Impact factor: 5.858

2.  An improved and simplified radioisotopic assay for the determination of free and esterified carnitine.

Authors:  J D McGarry; D W Foster
Journal:  J Lipid Res       Date:  1976-05       Impact factor: 5.922

Review 3.  Carnitine as an essential nutrient.

Authors:  P R Borum; S G Bennett
Journal:  J Am Coll Nutr       Date:  1986       Impact factor: 3.169

4.  Decreased serum carnitine in valproate induced Reye syndrome.

Authors:  H Böhles; K Richter; E Wagner-Thiessen; H Schäfer
Journal:  Eur J Pediatr       Date:  1982-11       Impact factor: 3.183

5.  Systemic carnitine deficiency simulating recurrent Reye syndrome.

Authors:  A M Glasgow; G Eng; A G Engel
Journal:  J Pediatr       Date:  1980-05       Impact factor: 4.406

6.  Turnover of carnitine by rat tissues.

Authors:  D E Brooks; J E McIntosh
Journal:  Biochem J       Date:  1975-06       Impact factor: 3.857

Review 7.  Carnitine deficiency, organic acidemias, and Reye's syndrome.

Authors:  D A Stumpf; W D Parker; C Angelini
Journal:  Neurology       Date:  1985-07       Impact factor: 9.910

8.  Chronic valproate administration reduces fasting ketonemia in children.

Authors:  J H Thurston; J E Carroll; W E Dodson; R E Hauhart; V Tasch
Journal:  Neurology       Date:  1983-10       Impact factor: 9.910

9.  Carnitine deficiency and hyperammonemia associated with valproic acid therapy.

Authors:  Y Ohtani; F Endo; I Matsuda
Journal:  J Pediatr       Date:  1982-11       Impact factor: 4.406

10.  Carnitine status in Reye and Reye-like syndromes.

Authors:  I Matsuda; Y Ohtani
Journal:  Pediatr Neurol       Date:  1986 Mar-Apr       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.